/
/
Shawn Harriman, Ph.D.
1/1
Number of views:
1000

Shawn Harriman, Ph.D.

Chief Development Officer

       Shawn Harriman, Ph.D., joined Frontera Therapeutics in April 2021 as the Chief Development Officer, Head of Research and Development,a role to which he brings over 25 years of experience as a scientist and organization leader in the pharmaceutical and biotechnology industries. During his tenure in industry, he contributed to shaping a portfolio of effective agents to treat diseases across multiple therapeutic areas, using a mixture of internal resource, industrial and academic collaborations, and strategic outsourcing. He has extensive experience successfully translating multiple medicinal candidates into clinical development across a diverse set of modalities (small molecules, peptides, siRNA, antibody-drug conjugates, RNA-based therapies, and gene therapy). Before joining Frontera, Dr, Harriman was Vice President of Translational Sciences at Sarepta Therapeutics. In this position, he was responsible for the leadership, operational, and strategic management of the Translational Sciences function within the R&D organization. In this role, he was responsible for biological validation of numerous neuromuscular disease targets, quantitative biology/pharmacology, DMPK, M&S, in vitro and in vivo model development, quantitative assay development and implementation, preclinical safety, and clinical biomarkers) to advance both RNA oligonucleotide and AAV-based gene therapy candidates from discovery to the clinic and post-marketing activities. At Sarepta, Dr. Harriman was a key contributor in the company obtaining accelerated FDA approval of two medicinal products, Vyondys and Amondys for the treatment of Duchenne Muscular Dystrophy (DMD). Additionally, he was responsible for progressing multiple peptide-conjugated phosphorodiamidate morpholino oligomers and AAV-based gene therapy preclinical candidates into advanced clinical evaluation in patients. Prior to Sarepta, Dr. Harriman was the Vice President of Preclinical Development and Clinical Pharmacology at Summit Therapeutics where he led Summit’s global discovery and preclinical organization towards the discovery and development of novel therapies for the treatment of Duchenne muscular dystrophy (DMD). Before his time at Summit, he held positions of increasing leadership responsibility during his 17+-year tenure in big pharma (Pfizer and Novartis) where he was responsible for establishing and leading the Metabolism and Pharmacokinetics Department. In this role, Dr. Harriman made significant contributions to the advancement of new medical entities spanning multiple therapeutic areas including, Oncology, Metabolic Diseases, Cardiovascular, Infectious Disease and Ophthalmology which culminated to over 30 INDs.
       Dr. Harriman received a B.S. in Zoology and an M.S. in Pharmaceutical Sciences from the University of Rhode Island. Dr. Harriman received his Ph.D. in Medicinal Chemistry from the University of Kansas and completed his postdoctoral research at Massachusetts Institute of Technology.
Retail price
0.0
Market price
0.0
Number of views:
1000
Product serial number
Quantity
-
+
1
Resume description

Shawn Harriman, Ph.D., joined Frontera Therapeutics in April 2021 as the Chief Development Officer, Head of Research and Development,a role to which he brings over 25 years of experience as a scientist and organization leader in the pharmaceutical and biotechnology industries. During his tenure in industry, he contributed to shaping a portfolio of effective agents to treat diseases across multiple therapeutic areas, using a mixture of internal resource, industrial and academic collaborations, and strategic outsourcing.  He has extensive experience successfully translating multiple medicinal candidates into clinical development across a diverse set of modalities (small molecules, peptides, siRNA, antibody-drug conjugates, RNA-based therapies, and gene therapy). Before joining Frontera, Dr, Harriman was Vice President of Translational Sciences at Sarepta Therapeutics.  In this position, he was responsible for the leadership, operational, and strategic management of the Translational Sciences function within the R&D organization. In this role, he was responsible for biological validation of numerous neuromuscular disease targets, quantitative biology/pharmacology, DMPK, M&S, in vitro and in vivo model development, quantitative assay development and implementation, preclinical safety, and clinical biomarkers) to advance both RNA oligonucleotide and AAV-based gene therapy candidates from discovery to the clinic and post-marketing activities. At Sarepta, Dr. Harriman was a key contributor in the company obtaining accelerated FDA approval of two medicinal products, Vyondys and Amondys for the treatment of Duchenne Muscular Dystrophy (DMD).  Additionally, he was responsible for progressing multiple peptide-conjugated phosphorodiamidate morpholino oligomers and AAV-based gene therapy preclinical candidates into advanced clinical evaluation in patients. Prior to Sarepta, Dr. Harriman was the Vice President of Preclinical Development and Clinical Pharmacology at Summit Therapeutics where he led Summit’s global discovery and preclinical organization towards the discovery and development of novel therapies for the treatment of Duchenne muscular dystrophy (DMD).  Before his time at Summit, he held positions of increasing leadership responsibility during his 17+-year tenure in big pharma (Pfizer and Novartis) where he was responsible for establishing and leading the Metabolism and Pharmacokinetics Department.  In this role, Dr. Harriman made significant contributions to the advancement of new medical entities spanning multiple therapeutic areas including, Oncology, Metabolic Diseases, Cardiovascular, Infectious Disease and Ophthalmology which culminated to over 30 INDs.

Dr. Harriman received a B.S. in Zoology and an M.S. in Pharmaceutical Sciences from the University of Rhode Island. Dr. Harriman received his Ph.D. in Medicinal Chemistry from the University of Kansas and completed his postdoctoral research at Massachusetts Institute of Technology.

Keyword:
shawn
and
of
the
in
he
to
was
harriman
development
We could not find any corresponding parameters, please add them to the properties table
Copyright ©2021-2029 Frontera Therapeutics Inc. All Rights Reserved.